ONESOURCE · Healthcare
Onesource Specialty Pharma Ltd. reported revenue of ₹376 cr for July to September 2025, +12.6% on the year and +15.0% on the quarter. Over the last four quarters revenue comes to ₹1,522 cr, +101.6% on the four before.
Operating profit (EBITDA) was ₹106 cr, a margin of 28.2%, +514 bps on the year and +128 bps on the quarter. Over the last 8 quarters the margin has ranged from −17.9% to 43.0%, averaging 19.6%. Operating costs grew +5.1% against revenue growth of +12.6%, so more of each rupee of sales reached operating profit.
The company swung to a net profit of ₹10.0 cr from a loss of ₹42.0 cr a year earlier, with earnings per share of ₹0.92.
On earnings per share of ₹3.49 over the last four quarters, the stock at ₹1,408.00 trades at 403.4 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
Half or more of pre-tax profit came from other income. What is it, and does it repeat?
Other income was 50% of profit before tax.
Source: Quarterly statements
A tax credit added to profit this quarter. Deferred tax recognised, or a reversal?
Profit before tax ₹6.0 cr; tax −₹5.0 cr, a credit.
Source: Quarterly statements
Turned profitable from a loss a year ago.
Net profit ₹10.0 cr against a loss of −₹42.0 cr.
Source: Quarterly statements
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹56.0 cr | ₹73.0 cr | ₹292 cr | ₹334 cr | ₹393 cr | ₹426 cr | ₹327 cr | ₹376 cr | ₹290 cr | ₹428 cr | ₹449 cr | ₹516 cr |
| YoY | — | — | — | +882% | +602% | +484% | +12% | +13% | −26% | +0% | +37% | +37% |
| EBITDA margin | −17.9% | −4.1% | 21.9% | 23.1% | 36.1% | 43.0% | 26.9% | 28.2% | 5.9% | 21.5% | 27.4% | 31.6% |
| Other income, % of PBT | — | — | — | — | — | 2% | — | 50% | — | — | 0% | −2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | — | — | — | — | — | −19% | — | — | — | — | −23% | −9% |
| Net profit | −₹130 cr | −₹40.0 cr | −₹6.0 cr | −₹42.0 cr | −₹69.0 cr | ₹98.0 cr | ₹0.0 cr | ₹10.0 cr | −₹89.0 cr | ₹5.0 cr | ₹25.0 cr | ₹57.0 cr |
| YoY | — | — | — | — | — | — | — | — | — | −95% | — | +470% |
| Core profit YoY | — | — | — | — | — | — | — | — | −437% | −102% | — | +1,700% |
| EPS | — | — | — | — | −₹6.02 | ₹8.61 | −₹0.02 | ₹0.92 | −₹7.74 | ₹0.40 | ₹2.18 | ₹5.01 |
| Flags | · | · | · | 1 | 1 | 2 | ✓ | 2 | 1 | 1 | 1 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Onesource Specialty Pharma Ltd. reported revenue of ₹376 cr (+12.6% on the year) and net profit of ₹10.0 cr (— on the year) for July to September 2025.
2 checks raised a question: Half or more of pre-tax profit came from other income. What is it, and does it repeat?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.